Research Article: Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study
Introduction:
Chronic obstructive pulmonary disease (COPD) is common and costly, disproportionately affecting those with lower income and public insurance. – It has been estimated that the national annual COPD-attributable medical expenditure was $. billion in , and projections have estimated that US national medical costs could approach $ billion by . –
Read more